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Abstract: Background: Clinical behaviour of atypical meningiomas is not uniform. While, as a
group, they exhibit a high recurrence rate, some pursue a more benign course,
whereas others progress early. We aim to investigate the imaging and pathological
factors that predict risk of early tumour progression and to determine whether early
progression is related to outcome.
Methods: Adult patients with WHO grade II meningioma treated in 3 regional referral
centres between 2007 and 2014 were included. MRI and pathology characteristics
were assessed. Gross total resection (GTR) was defined as Simpson 1-3. Recurrence
was classified into early and late (≤ 24 months vs. > 24 months).
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Results: Among the 220 cases thirty-seven (16.8%) patients progressed within 24
months of operation. Independent predictors of early progression were subtotal
resection (STR) (p=0.005), parafalcine/parasagittal location (p=0.015), peritumoural
oedema (p=0.027) and mitotic index (MI) > 7 (p=0.007). Adjuvant radiotherapy was
negatively associated with early recurrence (p=0.046). Thirty two per cent of patients
with residual tumour and 26% after GTR received adjuvant radiotherapy. There was a
significantly lower proportion of favourable outcomes at last follow-up (mRS 0-1) in
patients with early recurrence (p=0.001).
Conclusions: Atypical meningiomas are a heterogeneous group of tumours with 16.8%
patients having recurrence within 24 months of surgery. Residual tumour,
parafalcine/parasagittal location, peritumoural oedema and a MI > 7 were all
independently associated with early recurrence. As administration of adjuvant
radiotherapy was not protocolised in this cohort any conclusions about benefits of
irradiation of WHO grade II meningiomas should be viewed with caution. Patients with
early recurrence had worse neurological outcome. While histological and imaging
characteristics provide some prognostic value further molecular characterisation of
atypical meningiomas is warranted to aid clinical decision making.
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Dear Editor-in-Chief, 
 
Please consider this paper for publication in Acta Neurochirurgica. 
 
Atypical meningiomas are a growing group of tumours due to changes in classification 
systems. They pose a significant therapeutic challenge due to their aggressive behavior. 
However, it is being increasingly recognised that atypical meningioma constitute a very 
heterogeneous group of tumours, some of which pursue a beningn course, while others are 
very aggressive.  
 
A lot of work has been done to date to describe characteristics that can be used to predict 
recurrence/progression of atypical meningiomas, with little consideration to their 
heterogeneity.  
 
Here, acknowledging the heterogeneity of this group of tumours, we aimed to describe factors 
that influence early aggressive behavior, defined as recurrence/progession within 24 months 
of surgery. We have identified subtotal resection, parafalcine/parasaggital location, 
peritumoural oedema and a mitotic index > 7 as factors independently related to early 
recurrence/progression. Furthermore, we have identified the use of adjuvant radiotherapy to 
be negatively related to early progression.  
 
Importantly, we have also demonstrated that early progression/recurrence is a significant 
factor in outcome prognostication, with patients who have had recurrence within 24 months 
of the original surgery showing significantly lower rates of good outcomes. This finding 
confirms the importance of our work and importance of recognising atypical meningiomas as 
a heterogeneous group.  
 
We believe, this work will be of direct relevance to the audience of Acta Neurochirurgica and 
will lead to future work aimed at using more refined methods to characterise atypical 
meningioma in order to develop more accurate treatment paradigms.  
 
With best regards 
 
Karol Budohoski, MD, PhD 
Department of Neurosurgery  
Addenbrooke's Hospital 
University of Cambridge 
UK 
 
Conflict of interest: MDJ, SL, MF, MJ are investigators in the The ROAM/EORTC-1308 
trial: Radiation versus Observation following surgical resection of Atypical Meningioma: 
study protocol for a randomised controlled trial. There is no other conflict of interest 
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Abstract 35 
Background: Clinical behaviour of atypical meningiomas is not uniform. While, as a group, they 36 
exhibit a high recurrence rate, some pursue a more benign course, whereas others progress early. We 37 
aim to investigate the imaging and pathological factors that predict risk of early tumour progression 38 
and to determine whether early progression is related to outcome. 39 
Methods: Adult patients with WHO grade II meningioma treated in 3 regional referral centres 40 
between 2007 and 2014 were included. MRI and pathology characteristics were assessed. Gross total 41 
resection (GTR) was defined as Simpson 1-3. Recurrence was classified into early and late (≤ 24 42 
months vs. > 24 months).  43 
Results: Among the 220 cases thirty-seven (16.8%) patients progressed within 24 months of 44 
operation. Independent predictors of early progression were subtotal resection (STR) (p=0.005), 45 
parafalcine/parasagittal location (p=0.015), peritumoural oedema (p=0.027) and mitotic index (MI) > 46 
7 (p=0.007). Adjuvant radiotherapy was negatively associated with early recurrence (p=0.046). 47 
Thirty-two per cent of patients with residual tumour and 26% after GTR received adjuvant 48 
radiotherapy. There was a significantly lower proportion of favourable outcomes at last follow-up 49 
(mRS 0-1) in patients with early recurrence (p=0.001).  50 
Conclusions: Atypical meningiomas are a heterogeneous group of tumours with 16.8% patients 51 
having recurrence within 24 months of surgery. Residual tumour, parafalcine/parasagittal location, 52 
peritumoural oedema and a MI > 7 were all independently associated with early recurrence. As 53 
administration of adjuvant radiotherapy was not protocolised in this cohort any conclusions about 54 
benefits of irradiation of WHO grade II meningiomas should be viewed with caution. Patients with 55 
early recurrence had worse neurological outcome. While histological and imaging characteristics 56 
provide some prognostic value further molecular characterisation of atypical meningiomas is 57 
warranted to aid clinical decision making.  58 
Key words: Atypical meningioma, early recurrence, early progression, predictors of recurrence   59 
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Introduction 60 
Intracranial meningiomas constitute 35% of all primary brain tumours and are generally considered 61 
benign.[38] Nevertheless, atypical meningiomas, which account for 20 - 35% of all meningiomas, 62 
have recurrence rates up to 50% and 10 year survival less then 80%.[3, 39, 45]  63 
There are numerous histological subtypes of meningioma, however, the WHO classification is 64 
typically used to determine the biological behaviour, i.e. the risk of recurrence or progression. Since 65 
the changes in diagnostic criteria introduced in 2000 there has been a significant increase in the 66 
reported incidence of WHO grade II tumours from approximately 5% before 2000 to 30% of all 67 
meningiomas in more recent series.[5, 8, 42] The median time to progression of atypical meningiomas 68 
is approximately 24 months,[4, 6, 14] and they remain a heterogeneous group of tumours with reports 69 
of tumour progression within 1 year of operation despite gross total resection (GTR).[52] Due to the 70 
heterogeneity there is no uniform treatment paradigm currently being used to treat atypical 71 
meningiomas. The role of adjuvant radiotherapy as well as the frequency and length of follow-up 72 
remain to be determined.[27] Few studies have aimed to identify the clinical and histological 73 
characteristics which can be used to predict recurrence and justify more aggressive treatment.[2, 8, 30, 74 
34, 37, 49, 51, 54, 57, 10, 12–14, 18–20, 22] Subtotal resection,[12–14, 22] brain invasion,[13, 37, 41, 75 
51, 54] high mitotic index (MI),[14, 41, 42, 54] high proliferation index (MIB-1/Ki-67),[12, 18] 76 
absence of EGFR receptor,[49] bone involvement,[20, 37] progression form WHO grade I,[11, 14, 77 
59] have all been implicated in prognosis.  78 
Nevertheless, there remains a paucity of data concerning the exact timing of progression and its 79 
implication for prognosis. The aim of this study is to identify routinely available imaging and 80 
histological characteristics that may be associated with early with recurrence/progression, and 81 
progression/recurrence of WHO grade II meningiomas.  82 
 83 
Methods  84 
Retrospective analysis of all meningiomas from the histopathological records of three regional 85 
neurosurgery units teaching. All patients diagnosed as WHO grade II meningioma were included. 86 
Only patients diagnosed before 2014 were included to allow minimum 2 year follow up. Each 87 
Institutional Review Board approved this study. 88 
Early aggressive behaviour was defined as radiological recurrence or progression (see below for 89 
definitions) within the first two years after definitive treatment with surgery (with or without adjuvant 90 
radiotherapy). Radiological recurrence/progression was defined as new solid enhancing tumour.  91 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 5 
Clinical and patient characteristic used in the analysis included: age at diagnosis, gender, presence of 92 
residual tumour on post-operative MRI scan, the use of adjuvant radiotherapy, recurrence of tumour 93 
on follow-up imaging, time to recurrence, number of surgeries. Extent of resection was determined 94 
based on post-operative MRI (median time from surgery to imaging 23 days) and/or intraoperative 95 
findings. If postoperative imaging and intraoperative findings were in disagreement the modality that 96 
demonstrated residual was favoured. Subtotal resection (STR) was defined as a persistent area of 97 
contrast uptake within part of the volume of the original tumour on post-operative MRI scan or when 98 
operative report stated that residual tumour was left, i.e. Simpson grades 4 and 5. Gross total resection 99 
(GTR) was defined as Simpson 1 -3. Recurrence was defined as presence of tumour where there was 100 
no tumour on post-operative MRI. Progression of tumour was defined as any detected increase in size 101 
of residual tumour documented on follow up MRI imaging. Adjuvant radiotherapy was defined as 102 
radiotherapy administered to the tumour bed within 6 months of surgery to prevent rather than treat 103 
progression/recurrence. We did not stratify patients depending on whether stereotactic radiosurgery or 104 
fractionated radiotherapy was performed.  105 
Imaging characteristics included: location of tumour, involvement of dural sinus, bone erosion, 106 
irregularity of margins and presence of peritumoural oedema on pre-operative imaging (Figure 1). 107 
Location of tumour divided into: convexity, parafalcine/parasagittal and skull base. Sinus and bone 108 
involvement was determined based on the pre-operative imaging, surgical findings and/or pathology 109 
reports. Irregularity of margins was determined on pre-operative contrast enhanced T1 MRI scan and 110 
was defined as margins displaying at least one area of irregularity, daughter nodule or area of 111 
mushrooming.[36] Peritumoural oedema was determined on pre-operative MRI scans and was defined 112 
as T2 hyperintensity seen within the brain surrounding the contrast enhancing tumour (after excluding 113 
other possible causes, e.g. known infarct, multiple sclerosis etc.).  114 
Pathology characteristics included: brain invasion (brain invasion was only labelled as present or 115 
absent when brain tissue was included in the sample), atypia, necrosis, MI (reported as number of 116 
mitotic figures seen per 10 high power fields [HPF]) objective x 40 and MIB1 count. All pathology 117 
reports underwent central review to confirm diagnosis was in keeping with 2016 WHO criteria. 118 
All patients had a minimum of two years of follow up. Outcome was categorised using the modified 119 
Rankin Scale (mRS) at the last available clinic appointment. For statistical analysis, patients were 120 
dichotomised into those with favourable (mRS 0-1) and unfavourable (mRS ≥ 2) outcomes.  121 
Statistical analysis 122 
The median time to recurrence/progression was determined. Patients in whom recurrence/progression 123 
was seen before the median time (as defined for the whole cohort) were included in the 'early 124 
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recurrence/progression'. Patients in whom recurrence/progression was seen after the median time (as 125 
defined for the whole cohort), or those did not progress until last follow up, were labelled as 'others'.  126 
Receiver operator characteristic (ROC) curve data was used to dichotomise continuous variables such 127 
as MI and MIB1. MI was dichotomised at >7/10 high power fields (HPF) while MIB1 was 128 
dichotomised at >15%. 129 
 130 
Kaplan-Meier curves with Mantel Cox test were used to assess relationships between patient/clinical, 131 
radiological and pathology factors and progression-free survival. Multivariate logistic regression was 132 
used to determine factors independently associated with early recurrence/progression. Variables found 133 
significant on univariate analysis were included in the multivariate model. Sensitivity analysis for 134 
factors found to be independently associated with early recurrence was performed. Chi square was 135 
used to determine whether early recurrence/progression is associated with worse outcomes in patients 136 
with atypical meningioma.  137 
Statistical analysis was performed using SPSS software (SPSS, IBM, USA).  138 
 139 
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 7 
Results 141 
We identified 220 patients diagnosed with WHO II atypical meningiomas (Table 1). Data for extent 142 
of resection was available for 205 patients. GTR was achieved in 143 patients. Mean (overall survival 143 
has not reached a median, hence mean reported) overall survival (OS) for the whole cohort was 159 144 
months while median progression free survival (PFS) was 68 months. Five and 10-year OS was 87% 145 
and 69% PFR was 59% and 19%. 146 
 147 
Seventy-one patients (32%) had recurrence or progression. Of patients that recurred the median time 148 
to recurrence was 24 months (IQR 12-43). Patients who experienced tumour recurrence within 24 149 
months after treatment comprised the 'early recurrence/progression' group. Table 2 demonstrates the 150 
numbers of patients with early and any recurrence depending on extent of resection stratified by 151 
location. Briefly, of patients with GTR 12% had early recurrence, 27% had any recurrence at last 152 
follow up. On the other hand, of the patients with STR 32% had early recurrence, 50% had any 153 
recurrence at last follow up. On univariate analysis extent of resection was significantly related to the 154 
rates of early (p=0.005) and any recurrence (p=0.002). However, when specific locations were 155 
examined only early recurrence of tumours located at the convexity, but not tumours in the 156 
parafalcine/parasagittal location, skull base, nor those involving the sinuses, seemed to be 157 
significantly higher in the STR group.  158 
 159 
Fifty-seven patients received adjuvant radiotherapy. Of those 35 received prophylactic adjuvant 160 
radiotherapy despite GTR, while 22 received underwent radiotherapy for residual. A further 34 161 
patients had radiotherapy for recurrence. Table 2 described the numbers of patients with recurrence 162 
stratified by the use of adjuvant radiotherapy.  163 
 164 
Figure 2 demonstrates the Kaplan-Meier plots for progression free survival stratified by extent of 165 
resection; the use of adjuvant radiotherapy; location of tumour; and presence of peritumoural oedema. 166 
Figure 3 demonstrates the Kaplan-Meier plots for progression free survival stratified by pathological 167 
characteristics of atypia; MI; and MIB1. On univariate analysis all factors apart from necrosis, 168 
presence of irregular margins and brain invasion were significantly associated with progression free 169 
survival.  170 
 171 
Independent predictors of early progression using multivariate logistic regression were STR 172 
(p=0.005), parafalcine/parasagittal location (p=0.015), oedema on pre-operative MRI (p=0.027) and 173 
MI>7 (p=0.007), while adjuvant radiotherapy was negatively associated with early progression 174 
(p=0.046) (Table 3). No other clinical, imaging, nor pathological characteristics were found to be 175 
independently associated with the risk of early recurrence. Of the 62 patients with STR, 20 (32%) 176 
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 8 
received adjuvant radiotherapy. A further 37 patients received adjuvant radiotherapy after GTR. 177 
When logistic regression was repeated including only patients who underwent GTR, the use of 178 
adjuvant radiotherapy was no longer negatively associated with early recurrence (p=0.37; OR 0.52 179 
[0.13-2.16]).  180 
The presence of oedema on pre-operative MRI had 92% sensitivity, and 30% specificity for predicting 181 
24-month recurrence. The sensitivity and specificity of MI > 7/10 HPF were more balanced, i.e. 71% 182 
and 75% respectively. STR had a sensitivity and specificity for predicting 24-month recurrence of 183 
54% and 75%, respectively.  184 
mRS scores were obtained at a median of 54 months post surgery. There was a significantly lower 185 
proportion of patients with favourable outcomes at last follow-up (defined as mRS 0-1) among 186 
patients with early recurrence/progression versus others (Figure 4; p=0.001). Furthermore, this 187 
difference remained significant when patients without recurrence were excluded from the analysis 188 
(Figure 4; p=0.036).  189 
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Discussion 191 
In this study we analysed the usefulness of the routinely available clinical, radiological and 192 
pathological characteristics in predicting early disease recurrence and/or progression within 24 193 
months of surgical treatment, in patients with WHO grade II meningioma. In our series, subtotal 194 
resection, parafalcine/parasagittal location, peritumoural oedema visible on pre-operative imaging and 195 
a mitotic index > 7/10 HPF were independently associated with early recurrence. Furthermore, in this 196 
cohort of patients the use of adjuvant radiotherapy was associated with a reduced rate of early 197 
recurrence within 24 months. Importantly, we also found that patients who exhibit early recurrence of 198 
WHO II meningioma have a less favourable functional outcome, both when compared with the 199 
overall population of patients with WHO II meningiomas as well as when compared with patients 200 
who had recurrence later than 24 months after treatment.  201 
Atypical meningioma is a heterogeneous group of tumours. There have been a number of reports 202 
looking into factors associated with progression free survival with multiple factors being implicated. 203 
Location,[14, 43] extent of resection,[12, 16, 18, 22, 23, 58] presence of atypia,[1] brain invasion,[29, 204 
37, 54, 56] high MI,[29, 40, 54, 56] high MIB1 labelling,[12, 16, 18, 40] bone involvement,[20, 29, 205 
37] use of adjuvant radiotherapy,[6, 15, 26, 53] and progression of the WHO grade (from a WHO I 206 
tumour).[59] However, others have shown that none of the above factors influence the recurrence rate 207 
or time to recurrence of atypical meningioma.[25]  208 
Extent of resection is a good predictor of the risk of recurrence of meningiomas.[12, 16, 18, 22, 23, 209 
58] Our study shows that this is relevant to WHO grade II meningiomas, such that STR was 210 
independently associated with early recurrence/progression within 24 months. In our study 54% of 211 
meningiomas with early recurrence/progression had a known residual. We have pragmatically used 212 
GTR vs. STR to define extent of resection, as we recognise that in our retrospective series involving 213 
multiple surgeons it was impossible to differentiate with sufficient rigour patients who underwent 214 
Simpson 1 vs. Simpson 2 vs. Simpson 3 resections. Consequently, our data do not provide 215 
information on the benefits of different Simpson grade resections separately. Furthermore, 216 
colinearities, undoubtedly, exist between the extent of resection and use of adjuvant radiotherapy. 217 
However, radiotherapy in this group of patients was not used in a systematic way, and only one third 218 
of patients with residual tumour received adjuvant radiotherapy while the other two thirds did not.  219 
Apart from subtotal resection, we identified only two radiological and one histological characteristics 220 
associated with early aggressive behaviour and recurrence/progression within 24 months after 221 
treatment. Only parafalcine/parasagittal location and peritumoural oedema seen on preoperative MRI 222 
were independently related to early recurrence. Some reports have suggested there may be a 223 
relationship between location and recurrence rate of meningiomas.[14, 43] Whether there is a certain 224 
biological makeup of tumours related to their location which predisposes to recurrence is 225 
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unknown.[17] It is likely that overall higher recurrence rates observed in parafalcine/parasagittal 226 
location is representative of only being able to achieve STR in this location with residual tumour 227 
invading the superior sagittal sinus. Fifty per cent of patients with tumours in the 228 
parafalcine/parasagittal location were known to have a residual visible on post-operative imaging. 229 
Nevertheless, univariate analysis demonstrated that early recurrence rates were close to 40% 230 
regardless of whether GTR or STR was achieved. Although, we do not have data on the genetic 231 
makeup of the tumours in this location, nor do we have more detailed descriptions of extent of 232 
resection than post operative imaging and operative reports to make definitive statements, we believe 233 
that both the univariate and multivariate analysis confirm higher early recurrence rates in 234 
parafalcine/parasagittal meningiomas irrespectively of the extent of resection. Furthermore, while 235 
Simpson grade 1 resection would be desirable if recurrence was the only consideration, in real life 236 
there are many other important considerations, not least widely published morbidity related to radical 237 
resection of meningiomas invading venous sinuses.[24, 48] The judicious use of stereotactic 238 
radiosurgery following incomplete resection of parasagittal meningiomas reduces recurrence rates to 239 
similar as those seen with Simpson grade 1 resections.[35] Our data does not support pursuing radical 240 
resection in parafalcine/parasagittal meningiomas at the expense of morbidity 241 
In this cohort brain invasion was not found to be associated with early tumour recurrence. It is widely 242 
accepted that diagnosis of brain invasion using operative samples is difficult as frequently brain tissue 243 
is not included in the sample.[9] We were not able to ascertain whether the samples provided for 244 
central review were representative for assessing brain invasions and this constitutes a limitation of this 245 
study. We have, however, re-analysed our data including only samples where brain tissue was present 246 
and a definitive statement about brain invasion could have been made. However, this analysis did not 247 
change the result and brain invasion was not found to be independently associated with early 248 
recurrence on multivariate analysis in this limited sample. 249 
Our understanding of the pathophysiology of peritumoural oedema associated with meningiomas 250 
remains incomplete. Previous studies have implicated size,[21] growth rate,[50] leptomeningeal 251 
invasion, development of pial blood supply,[33, 55] as well as specific histological types[7, 33] with 252 
development of peritumoural brain oedema. In our series the presence of peritumoural oedema was 253 
significantly associated with early aggressive behaviour and recurrence at 24-months. Oedema had a 254 
92% and 30% sensitivity and specificity, respectively, suggesting it may be used as a guide to 255 
determine frequency of surveillance but may not be specific enough to warrant routine delivery of 256 
adjuvant radiotherapy. 257 
The histological diagnosis of atypical meningioma is based on the presence of the following: high MI 258 
4-19/10 HPF, specific features of atypia (hypercellularity, prominent nucleoli, diffuse growth pattern, 259 
necrosis and small cell change), or brain invasion. Of those routinely available histological parameters 260 
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(and MIB1 labelling) only a MI>7/10 HPF was independently associated with early progression in our 261 
study. Indeed a high MI has been previously reported to be related to overall recurrence of atypical 262 
meningioma, but not early recurrence.[18, 40, 54, 56] As atypical meningiomas have a narrowly 263 
defined range of MI the value of this parameter is likely diminished. For this reason most studies do 264 
not give a threshold MI related to recurrence, but treat the presence of high MI (i.e. >4/10 HPF) as a 265 
factor. In this study, based on a ROC curve analysis, 7 mitoses/10 HPF was determined as the 266 
threshold value in our study. This is in keeping with a report by Sun et al.[54] who also found 267 
MI>7/10 HPF related to a higher rate of recurrence in completely resected atypical meningiomas 268 
(particularly in the absence of brain invasion). MI>7/10 HPF had a sensitivity of 71% and specificity 269 
of 75% for predicting 24-month recurrence. No other histological characteristic was associated with 270 
early recurrence. It  271 
The role of adjuvant radiotherapy in the management of atypical meningioma is not fully defined.[28] 272 
Similarly to our study literature typically reports results of radiotherapy independently of the extent of 273 
resection as well as tumour location. While a relationship between reduced rates of recurrence and the 274 
use of adjuvant radiotherapy following surgery for atypical meningiomas, has been previously 275 
shown,[6, 15, 26, 53] there have been individual reports raising concern that, in fact, radiotherapy 276 
may transform meningiomas into more aggressive or anaplastic types.[31, 44] Indeed, in a series of 277 
610 meningiomas, a 2.2% rate of malignant transformation at a median of 4.9 years after SRS has 278 
been reported.[44] In our series 56 patients underwent adjuvant radiotherapy, however, only one third 279 
of those patients had residual tumour, while the other two thirds were prophylactically irradiated 280 
based on patient and clinician preference on the premise of preventing future recurrence. In our study 281 
adjuvant radiotherapy was independently associated with a reduced risk of early 282 
recurrence/progression when all patients were analysed. However, this was not the case when only 283 
patients with GTR were analysed suggesting there may be less benefit in prophylactic adjuvant 284 
radiation. Due to the variable clinical indications for adjuvant radiotherapy and the inherent bias this 285 
introduces we cannot conclude that radiotherapy should be used for all patients. Two large, 286 
multicentre international randomised controlled trials will are in progress and will ultimately address 287 
the role of early adjuvant radiotherapy for atypical meningioma.[27, 32]  288 
Whilst our data do not provide definitive answers, we can postulate that early progression/recurrence 289 
of atypical meningioma may be related as much to the aggressiveness of treatment as well as 290 
biological makeup of the specific tumours. While some characteristics routinely available in clinical 291 
practice can aid in prognostication and are very important for day-to-day treatment decisions, this 292 
study further demonstrates the heterogeneity of atypical meningiomas and the need for developing 293 
risk stratification tools, which go beyond the WHO grading system. A number of mutations as well as 294 
DNA methylation profiles have all been shown to be linked with the risk of recurrence in 295 
meningioma.[46, 47] Addition of molecular markers has the potential to significantly improve not 296 
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only understanding of the biology of meningioma, but refine prognostic and treatment stratification as 297 
well as development of more targeted treatment modalities. Importantly, this study has demonstrated 298 
that early recurrence/progression of atypical meningioma was significantly related to neurological 299 
outcomes. Therefore, identification of clinical and biological and molecular predictors of recurrence is 300 
crucial to rationally stratify management decisions.  301 
Our study has several limitations, which need to be acknowledged. Firstly as a retrospective analysis 302 
we relied on clinical documentation, particularly related to extent of resection. While we have taken 303 
all possible measures to minimise this bias we are aware that inaccuracies could have been 304 
introduced. Overall survival in patients with meningiomas is difficult to ascertain, as long observation 305 
periods are required. The available survival data only allowed an analysis of all cause mortality, rather 306 
than tumour specific mortality. Furthermore, we did not have age matched life expectancy data for 307 
comparison. Survival in patients with meningiomas is difficult to ascertain, as long observation 308 
periods are required, however, our data concentrates on early recurrence within 2 years and all 309 
patients reported have sufficient follow up for this assessment. Whilst there was a trend towards better 310 
tumour control in those treated with radiotherapy this needs to be further evaluate and two 311 
international phase III trials are ongoing (NRG BN-003 312 
(http://clinicaltrials.gov/ct2/show/NCT03180268) and the ROAM trial (http://roam-trial.org.uk)). 313 
Finally, while central pathology review was possible to determine the MIB1 and MI we were not able 314 
to review all pathology slides to comprehensively assess brain invasion and instead we had to rely on 315 
available pathology reports. 316 
Conclusions 317 
We have identified a specific group of tumours within this cohort of atypical meningioma 318 
characterised by early aggressive behaviour and recurrence within 24 months after initial surgical 319 
treatment. We have demonstrated that such early recurrence was related to poor neurological 320 
outcome.  321 
Parafalcine/parasagittal location, peritumoural oedema on pre-operative MRI scan as well as a 322 
MI>7/10hpf were positively associated, while the use of adjuvant radiotherapy was negatively 323 
associated, with the risk of early recurrence. While the radiological and pathological characteristics 324 
were found to be sensitive, they were not specific enough to automatically mandate adjuvant 325 
treatment.  326 
We have demonstrated that adjuvant radiotherapy was associated with a reduced risk of early 327 
recurrence. Nevertheless, limited sample size and inconsistent use of radiotherapy in this cohort 328 
prevents us from making a definitive statement. The role of adjuvant radiotherapy remains to be 329 
determined in prospective studies.  330 
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Overall, the routinely available radiological and histological parameters are insufficient to accurately 331 
predict behaviour and stratify management of patients with this heterogeneous group of tumours. It is 332 
likely that molecular markers, like in other neoplastic diseases, will fill this void and future research 333 
should be focused in this direction. 334 
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Figure 1 519 
Examples of radiological characteristics used in the study. A: peritumoural oedema manifested as T2 520 
hyperintensity immediately surrounding the tumour with mass effect; B: irregular margins with 521 
'mushrooming' and nodules appearing as if detached from main mass of tumour; C: bone involvement 522 
in a parasagittal meningioma; D: sinus involvement manifest with tumour clearly present in the cavity 523 
of the superior sagittal sinus. 524 
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Figure 2 528 
Kaplan-Meier plots demonstrating a significant association between extent of resection; the use of 529 
adjuvant XRT; location (divided into convexity, parafalcine/parasagittal and skull base); peritumoural 530 
oedema and progression free survival for patients with atypical meningiomas. Log rank test for 531 
significance used to determine statistical significance.  532 
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Figure 3 536 
Kaplan-Meier plots demonstrating a significant association between presence of atypia; MI; MIB1 537 
count and progression free survival. MI has been dichotomised to MI ≤ 7/hpf and MI > 7/hpf and 538 
MIB1 has been dichotomised to MIB1 ≤ 15% and MIB1 > 15%. Log rank test for significance used to 539 
determine statistical significance. 540 
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Figure 4 544 
Bar chart demonstrating the difference in clinical outcomes between the 'early progression/recurrence' 545 
groups. All others (top graph); below the same analysis is repeated excluding patient who never had a 546 
recurrence (bottom graph).  Dashed line depicts differences in number of patients with favourable 547 
outcomes defined as mRS 0-1 at last follow-up. mRS - modified Rankin Scale 548 
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Abstract 35 
Background: Clinical behaviour of atypical meningiomas is not uniform. While, as a group, they 36 
exhibit a high recurrence rate, some pursue a more benign course, whereas others progress early. We 37 
aim to investigate the imaging and pathological factors that predict risk of early tumour progression 38 
and to determine whether early progression is related to outcome. 39 
Methods: Adult patients with WHO grade II meningioma treated in 3 regional referral centres 40 
between 2007 and 2014 were included. MRI and pathology characteristics were assessed. Gross total 41 
resection (GTR) was defined as Simpson 1-3. Recurrence was classified into early and late (≤ 24 42 
months vs. > 24 months).  43 
Results: Among the 220 cases thirty-seven (16.8%) patients progressed within 24 months of 44 
operation. Independent predictors of early progression were subtotal resection (STR) (p=0.005), 45 
parafalcine/parasagittal location (p=0.015), peritumoural oedema (p=0.027) and mitotic index (MI) > 46 
7 (p=0.007). Adjuvant radiotherapy was negatively associated with early recurrence (p=0.046). 47 
Thirty-two per cent of patients with residual tumour and 26% after GTR received adjuvant 48 
radiotherapy. There was a significantly lower proportion of favourable outcomes at last follow-up 49 
(mRS 0-1) in patients with early recurrence (p=0.001).  50 
Conclusions: Atypical meningiomas are a heterogeneous group of tumours with 16.8% patients 51 
having recurrence within 24 months of surgery. Residual tumour, parafalcine/parasagittal location, 52 
peritumoural oedema and a MI > 7 were all independently associated with early recurrence. As 53 
administration of adjuvant radiotherapy was not protocolised in this cohort any conclusions about 54 
benefits of irradiation of WHO grade II meningiomas should be viewed with caution. Patients with 55 
early recurrence had worse neurological outcome. While histological and imaging characteristics 56 
provide some prognostic value further molecular characterisation of atypical meningiomas is 57 
warranted to aid clinical decision making.  58 
Key words: Atypical meningioma, early recurrence, early progression, predictors of recurrence   59 
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Introduction 60 
Intracranial meningiomas constitute 35% of all primary brain tumours and are generally considered 61 
benign.[38] Nevertheless, atypical meningiomas, which account for 20 - 35% of all meningiomas, 62 
have recurrence rates up to 50% and 10 year survival less then 80%.[3, 39, 45]  63 
There are numerous histological subtypes of meningioma, however, the WHO classification is 64 
typically used to determine the biological behaviour, i.e. the risk of recurrence or progression. Since 65 
the changes in diagnostic criteria introduced in 2000 there has been a significant increase in the 66 
reported incidence of WHO grade II tumours from approximately 5% before 2000 to 30% of all 67 
meningiomas in more recent series.[5, 8, 42] The median time to progression of atypical meningiomas 68 
is approximately 24 months,[4, 6, 14] and they remain a heterogeneous group of tumours with reports 69 
of tumour progression within 1 year of operation despite gross total resection (GTR).[52] Due to the 70 
heterogeneity there is no uniform treatment paradigm currently being used to treat atypical 71 
meningiomas. The role of adjuvant radiotherapy as well as the frequency and length of follow-up 72 
remain to be determined.[27] Few studies have aimed to identify the clinical and histological 73 
characteristics which can be used to predict recurrence and justify more aggressive treatment.[2, 8, 30, 74 
34, 37, 49, 51, 54, 57, 10, 12–14, 18–20, 22] Subtotal resection,[12–14, 22] brain invasion,[13, 37, 41, 75 
51, 54] high mitotic index (MI),[14, 41, 42, 54] high proliferation index (MIB-1/Ki-67),[12, 18] 76 
absence of EGFR receptor,[49] bone involvement,[20, 37] progression form WHO grade I,[11, 14, 77 
59] have all been implicated in prognosis.  78 
Nevertheless, there remains a paucity of data concerning the exact timing of progression and its 79 
implication for prognosis. The aim of this study is to identify routinely available imaging and 80 
histological characteristics that may be associated with early recurrence/progression, and 81 
progression/recurrence of WHO grade II meningiomas.  82 
 83 
Methods  84 
Retrospective analysis of all meningiomas from the histopathological records of three regional 85 
neurosurgery units teaching. All patients diagnosed as WHO grade II meningioma were included. 86 
Only patients diagnosed before 2014 were included to allow minimum 2 year follow up. Each 87 
Institutional Review Board approved this study. 88 
Early aggressive behaviour was defined as radiological recurrence or progression (see below for 89 
definitions) within the first two years after definitive treatment with surgery (with or without adjuvant 90 
radiotherapy). Radiological recurrence/progression was defined as new solid enhancing tumour.  91 
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 5 
Clinical and patient characteristic used in the analysis included: age at diagnosis, gender, presence of 92 
residual tumour on post-operative MRI scan, the use of adjuvant radiotherapy, recurrence of tumour 93 
on follow-up imaging, time to recurrence, number of surgeries. Extent of resection was determined 94 
based on post-operative MRI (median time from surgery to imaging 23 days) and/or intraoperative 95 
findings. If postoperative imaging and intraoperative findings were in disagreement the modality that 96 
demonstrated residual was favoured. Subtotal resection (STR) was defined as a persistent area of 97 
contrast uptake within part of the volume of the original tumour on post-operative MRI scan or when 98 
operative report stated that residual tumour was left, i.e. Simpson grades 4 and 5. Gross total resection 99 
(GTR) was defined as Simpson 1 -3. Recurrence was defined as presence of tumour where there was 100 
no tumour on post-operative MRI. Progression of tumour was defined as any detected increase in size 101 
of residual tumour documented on follow up MRI imaging. Adjuvant radiotherapy was defined as 102 
radiotherapy administered to the tumour bed within 6 months of surgery to prevent rather than treat 103 
progression/recurrence. We did not stratify patients depending on whether stereotactic radiosurgery or 104 
fractionated radiotherapy was performed.  105 
Imaging characteristics included: location of tumour, involvement of dural sinus, bone erosion, 106 
irregularity of margins and presence of peritumoural oedema on pre-operative imaging (Figure 1). 107 
Location of tumour divided into: convexity, parafalcine/parasagittal and skull base. Sinus and bone 108 
involvement was determined based on the pre-operative imaging, surgical findings and/or pathology 109 
reports. Irregularity of margins was determined on pre-operative contrast enhanced T1 MRI scan and 110 
was defined as margins displaying at least one area of irregularity, daughter nodule or area of 111 
mushrooming.[36] Peritumoural oedema was determined on pre-operative MRI scans and was defined 112 
as T2 hyperintensity seen within the brain surrounding the contrast enhancing tumour (after excluding 113 
other possible causes, e.g. known infarct, multiple sclerosis etc.).  114 
Pathology characteristics included: brain invasion (brain invasion was only labelled as present or 115 
absent when brain tissue was included in the sample), atypia, necrosis, MI (reported as number of 116 
mitotic figures seen per 10 high power fields [HPF]) objective x 40 and MIB1 count. All pathology 117 
reports underwent central review to confirm diagnosis was in keeping with 2016 WHO criteria. 118 
All patients had a minimum of two years of follow up. Outcome was categorised using the modified 119 
Rankin Scale (mRS) at the last available clinic appointment. For statistical analysis, patients were 120 
dichotomised into those with favourable (mRS 0-1) and unfavourable (mRS ≥ 2) outcomes.  121 
Statistical analysis 122 
The median time to recurrence/progression was determined. Patients in whom recurrence/progression 123 
was seen before the median time (as defined for the whole cohort) were included in the 'early 124 
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recurrence/progression'. Patients in whom recurrence/progression was seen after the median time (as 125 
defined for the whole cohort), or those did not progress until last follow up, were labelled as 'others'.  126 
Receiver operator characteristic (ROC) curve data was used to dichotomise continuous variables such 127 
as MI and MIB1. MI was dichotomised at >7/10 high power fields (HPF) while MIB1 was 128 
dichotomised at >15%. 129 
 130 
Kaplan-Meier curves with Mantel Cox test were used to assess relationships between patient/clinical, 131 
radiological and pathology factors and progression-free survival. Multivariate logistic regression was 132 
used to determine factors independently associated with early recurrence/progression. Variables found 133 
significant on univariate analysis were included in the multivariate model. Sensitivity analysis for 134 
factors found to be independently associated with early recurrence was performed. Chi square was 135 
used to determine whether early recurrence/progression is associated with worse outcomes in patients 136 
with atypical meningioma.  137 
Statistical analysis was performed using SPSS software (SPSS, IBM, USA).  138 
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 7 
Results 141 
We identified 220 patients diagnosed with WHO II atypical meningiomas (Table 1). Data for extent 142 
of resection was available for 205 patients. GTR was achieved in 143 patients. Mean (overall survival 143 
has not reached a median, hence mean reported) overall survival (OS) for the whole cohort was 159 144 
months while median progression free survival (PFS) was 68 months. Five and 10-year OS was 87% 145 
and 69% PFR was 59% and 19%. 146 
 147 
Seventy-one patients (32%) had recurrence or progression. Of patients that recurred the median time 148 
to recurrence was 24 months (IQR 12-43). Patients who experienced tumour recurrence within 24 149 
months after treatment comprised the 'early recurrence/progression' group. Table 2 demonstrates the 150 
numbers of patients with early and any recurrence depending on extent of resection stratified by 151 
location. Briefly, of patients with GTR 12% had early recurrence, 27% had any recurrence at last 152 
follow up. On the other hand, of the patients with STR 32% had early recurrence, 50% had any 153 
recurrence at last follow up. On univariate analysis extent of resection was significantly related to the 154 
rates of early (p=0.005) and any recurrence (p=0.002). However, when specific locations were 155 
examined only early recurrence of tumours located at the convexity, but not tumours in the 156 
parafalcine/parasagittal location, skull base, nor those involving the sinuses, seemed to be 157 
significantly higher in the STR group.  158 
 159 
Fifty-seven patients received adjuvant radiotherapy. Of those 35 received prophylactic adjuvant 160 
radiotherapy despite GTR, while 22 received underwent radiotherapy for residual. A further 34 161 
patients had radiotherapy for recurrence. Table 2 described the numbers of patients with recurrence 162 
stratified by the use of adjuvant radiotherapy.  163 
 164 
Figure 2 demonstrates the Kaplan-Meier plots for progression free survival stratified by extent of 165 
resection; the use of adjuvant radiotherapy; location of tumour; and presence of peritumoural oedema. 166 
Figure 3 demonstrates the Kaplan-Meier plots for progression free survival stratified by pathological 167 
characteristics of atypia; MI; and MIB1. On univariate analysis all factors apart from necrosis, 168 
presence of irregular margins and brain invasion were significantly associated with progression free 169 
survival.  170 
 171 
Independent predictors of early progression using multivariate logistic regression were STR 172 
(p=0.005), parafalcine/parasagittal location (p=0.015), oedema on pre-operative MRI (p=0.027) and 173 
MI>7 (p=0.007), while adjuvant radiotherapy was negatively associated with early progression 174 
(p=0.046) (Table 3). No other clinical, imaging, nor pathological characteristics were found to be 175 
independently associated with the risk of early recurrence. Of the 62 patients with STR, 20 (32%) 176 
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 8 
received adjuvant radiotherapy. A further 37 patients received adjuvant radiotherapy after GTR. 177 
When logistic regression was repeated including only patients who underwent GTR, the use of 178 
adjuvant radiotherapy was no longer negatively associated with early recurrence (p=0.37; OR 0.52 179 
[0.13-2.16]).  180 
The presence of oedema on pre-operative MRI had 92% sensitivity, and 30% specificity for predicting 181 
24-month recurrence. The sensitivity and specificity of MI > 7/10 HPF were more balanced, i.e. 71% 182 
and 75% respectively. STR had a sensitivity and specificity for predicting 24-month recurrence of 183 
54% and 75%, respectively.  184 
mRS scores were obtained at a median of 54 months post surgery. There was a significantly lower 185 
proportion of patients with favourable outcomes at last follow-up (defined as mRS 0-1) among 186 
patients with early recurrence/progression versus others (Figure 4; p=0.001). Furthermore, this 187 
difference remained significant when patients without recurrence were excluded from the analysis 188 
(Figure 4; p=0.036).  189 
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Discussion 191 
In this study we analysed the usefulness of the routinely available clinical, radiological and 192 
pathological characteristics in predicting early disease recurrence and/or progression within 24 193 
months of surgical treatment, in patients with WHO grade II meningioma. In our series, subtotal 194 
resection, parafalcine/parasagittal location, peritumoural oedema visible on pre-operative imaging and 195 
a mitotic index > 7/10 HPF were independently associated with early recurrence. Furthermore, in this 196 
cohort of patients the use of adjuvant radiotherapy was associated with a reduced rate of early 197 
recurrence within 24 months. Importantly, we also found that patients who exhibit early recurrence of 198 
WHO II meningioma have a less favourable functional outcome, both when compared with the 199 
overall population of patients with WHO II meningiomas as well as when compared with patients 200 
who had recurrence later than 24 months after treatment.  201 
Atypical meningioma is a heterogeneous group of tumours. There have been a number of reports 202 
looking into factors associated with progression free survival with multiple factors being implicated. 203 
Location,[14, 43] extent of resection,[12, 16, 18, 22, 23, 58] presence of atypia,[1] brain invasion,[29, 204 
37, 54, 56] high MI,[29, 40, 54, 56] high MIB1 labelling,[12, 16, 18, 40] bone involvement,[20, 29, 205 
37] use of adjuvant radiotherapy,[6, 15, 26, 53] and progression of the WHO grade (from a WHO I 206 
tumour).[59] However, others have shown that none of the above factors influence the recurrence rate 207 
or time to recurrence of atypical meningioma.[25]  208 
Extent of resection is a good predictor of the risk of recurrence of meningiomas.[12, 16, 18, 22, 23, 209 
58] Our study shows that this is relevant to WHO grade II meningiomas, such that STR was 210 
independently associated with early recurrence/progression within 24 months. In our study 54% of 211 
meningiomas with early recurrence/progression had a known residual. We have pragmatically used 212 
GTR vs. STR to define extent of resection, as we recognise that in our retrospective series involving 213 
multiple surgeons it was impossible to differentiate with sufficient rigour patients who underwent 214 
Simpson 1 vs. Simpson 2 vs. Simpson 3 resections. Consequently, our data do not provide 215 
information on the benefits of different Simpson grade resections separately. Furthermore, 216 
colinearities, undoubtedly, exist between the extent of resection and use of adjuvant radiotherapy. 217 
However, radiotherapy in this group of patients was not used in a systematic way, and only one third 218 
of patients with residual tumour received adjuvant radiotherapy while the other two thirds did not.  219 
Apart from subtotal resection, we identified only two radiological and one histological characteristics 220 
associated with early aggressive behaviour and recurrence/progression within 24 months after 221 
treatment. Only parafalcine/parasagittal location and peritumoural oedema seen on preoperative MRI 222 
were independently related to early recurrence. Some reports have suggested there may be a 223 
relationship between location and recurrence rate of meningiomas.[14, 43] Whether there is a certain 224 
biological makeup of tumours related to their location which predisposes to recurrence is 225 
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 10 
unknown.[17] It is likely that overall higher recurrence rates observed in parafalcine/parasagittal 226 
location is representative of only being able to achieve STR in this location with residual tumour 227 
invading the superior sagittal sinus. Fifty per cent of patients with tumours in the 228 
parafalcine/parasagittal location were known to have a residual visible on post-operative imaging. 229 
Nevertheless, univariate analysis demonstrated that early recurrence rates were close to 40% 230 
regardless of whether GTR or STR was achieved. Although, we do not have data on the genetic 231 
makeup of the tumours in this location, nor do we have more detailed descriptions of extent of 232 
resection than post operative imaging and operative reports to make definitive statements, we believe 233 
that both the univariate and multivariate analysis confirm higher early recurrence rates in 234 
parafalcine/parasagittal meningiomas irrespectively of the extent of resection. Furthermore, while 235 
Simpson grade 1 resection would be desirable if recurrence was the only consideration, in real life 236 
there are many other important considerations, not least widely published morbidity related to radical 237 
resection of meningiomas invading venous sinuses.[24, 48] The judicious use of stereotactic 238 
radiosurgery following incomplete resection of parasagittal meningiomas reduces recurrence rates to 239 
similar as those seen with Simpson grade 1 resections.[35] Our data does not support pursuing radical 240 
resection in parafalcine/parasagittal meningiomas at the expense of morbidity 241 
In this cohort brain invasion was not found to be associated with early tumour recurrence. It is widely 242 
accepted that diagnosis of brain invasion using operative samples is difficult as frequently brain tissue 243 
is not included in the sample.[9] We were not able to ascertain whether the samples provided for 244 
central review were representative for assessing brain invasions and this constitutes a limitation of this 245 
study. We have, however, re-analysed our data including only samples where brain tissue was present 246 
and a definitive statement about brain invasion could have been made. However, this analysis did not 247 
change the result and brain invasion was not found to be independently associated with early 248 
recurrence on multivariate analysis in this limited sample. 249 
Our understanding of the pathophysiology of peritumoural oedema associated with meningiomas 250 
remains incomplete. Previous studies have implicated size,[21] growth rate,[50] leptomeningeal 251 
invasion, development of pial blood supply,[33, 55] as well as specific histological types[7, 33] with 252 
development of peritumoural brain oedema. In our series the presence of peritumoural oedema was 253 
significantly associated with early aggressive behaviour and recurrence at 24-months. Oedema had a 254 
92% and 30% sensitivity and specificity, respectively, suggesting it may be used as a guide to 255 
determine frequency of surveillance but may not be specific enough to warrant routine delivery of 256 
adjuvant radiotherapy. 257 
The histological diagnosis of atypical meningioma is based on the presence of the following: high MI 258 
4-19/10 HPF, specific features of atypia (hypercellularity, prominent nucleoli, diffuse growth pattern, 259 
necrosis and small cell change), or brain invasion. Of those routinely available histological parameters 260 
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(and MIB1 labelling) only a MI>7/10 HPF was independently associated with early progression in our 261 
study. Indeed a high MI has been previously reported to be related to overall recurrence of atypical 262 
meningioma, but not early recurrence.[18, 40, 54, 56] As atypical meningiomas have a narrowly 263 
defined range of MI the value of this parameter is likely diminished. For this reason most studies do 264 
not give a threshold MI related to recurrence, but treat the presence of high MI (i.e. >4/10 HPF) as a 265 
factor. In this study, based on a ROC curve analysis, 7 mitoses/10 HPF was determined as the 266 
threshold value in our study. This is in keeping with a report by Sun et al.[54] who also found 267 
MI>7/10 HPF related to a higher rate of recurrence in completely resected atypical meningiomas 268 
(particularly in the absence of brain invasion). MI>7/10 HPF had a sensitivity of 71% and specificity 269 
of 75% for predicting 24-month recurrence. No other histological characteristic was associated with 270 
early recurrence. It  271 
The role of adjuvant radiotherapy in the management of atypical meningioma is not fully defined.[28] 272 
Similarly to our study literature typically reports results of radiotherapy independently of the extent of 273 
resection as well as tumour location. While a relationship between reduced rates of recurrence and the 274 
use of adjuvant radiotherapy following surgery for atypical meningiomas, has been previously 275 
shown,[6, 15, 26, 53] there have been individual reports raising concern that, in fact, radiotherapy 276 
may transform meningiomas into more aggressive or anaplastic types.[31, 44] Indeed, in a series of 277 
610 meningiomas, a 2.2% rate of malignant transformation at a median of 4.9 years after SRS has 278 
been reported.[44] In our series 56 patients underwent adjuvant radiotherapy, however, only one third 279 
of those patients had residual tumour, while the other two thirds were prophylactically irradiated 280 
based on patient and clinician preference on the premise of preventing future recurrence. In our study 281 
adjuvant radiotherapy was independently associated with a reduced risk of early 282 
recurrence/progression when all patients were analysed. However, this was not the case when only 283 
patients with GTR were analysed suggesting there may be less benefit in prophylactic adjuvant 284 
radiation. Due to the variable clinical indications for adjuvant radiotherapy and the inherent bias this 285 
introduces we cannot conclude that radiotherapy should be used for all patients. Two large, 286 
multicentre international randomised controlled trials will are in progress and will ultimately address 287 
the role of early adjuvant radiotherapy for atypical meningioma.[27, 32]  288 
Whilst our data do not provide definitive answers, we can postulate that early progression/recurrence 289 
of atypical meningioma may be related as much to the aggressiveness of treatment as well as 290 
biological makeup of the specific tumours. While some characteristics routinely available in clinical 291 
practice can aid in prognostication and are very important for day-to-day treatment decisions, this 292 
study further demonstrates the heterogeneity of atypical meningiomas and the need for developing 293 
risk stratification tools, which go beyond the WHO grading system. A number of mutations as well as 294 
DNA methylation profiles have all been shown to be linked with the risk of recurrence in 295 
meningioma.[46, 47] Addition of molecular markers has the potential to significantly improve not 296 
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only understanding of the biology of meningioma, but refine prognostic and treatment stratification as 297 
well as development of more targeted treatment modalities. Importantly, this study has demonstrated 298 
that early recurrence/progression of atypical meningioma was significantly related to neurological 299 
outcomes. Therefore, identification of clinical and biological and molecular predictors of recurrence is 300 
crucial to rationally stratify management decisions.  301 
Our study has several limitations, which need to be acknowledged. Firstly as a retrospective analysis 302 
we relied on clinical documentation, particularly related to extent of resection. While we have taken 303 
all possible measures to minimise this bias we are aware that inaccuracies could have been 304 
introduced. Overall survival in patients with meningiomas is difficult to ascertain, as long observation 305 
periods are required. The available survival data only allowed an analysis of all cause mortality, rather 306 
than tumour specific mortality. Furthermore, we did not have age matched life expectancy data for 307 
comparison. Survival in patients with meningiomas is difficult to ascertain, as long observation 308 
periods are required, however, our data concentrates on early recurrence within 2 years and all 309 
patients reported have sufficient follow up for this assessment. Whilst there was a trend towards better 310 
tumour control in those treated with radiotherapy this needs to be further evaluate and two 311 
international phase III trials are ongoing (NRG BN-003 312 
(http://clinicaltrials.gov/ct2/show/NCT03180268) and the ROAM trial (http://roam-trial.org.uk)). 313 
Finally, while central pathology review was possible to determine the MIB1 and MI we were not able 314 
to review all pathology slides to comprehensively assess brain invasion and instead we had to rely on 315 
available pathology reports. 316 
Conclusions 317 
We have identified a specific group of tumours within this cohort of atypical meningioma 318 
characterised by early aggressive behaviour and recurrence within 24 months after initial surgical 319 
treatment. We have demonstrated that such early recurrence was related to poor neurological 320 
outcome.  321 
Parafalcine/parasagittal location, peritumoural oedema on pre-operative MRI scan as well as a 322 
MI>7/10hpf were positively associated, while the use of adjuvant radiotherapy was negatively 323 
associated, with the risk of early recurrence. While the radiological and pathological characteristics 324 
were found to be sensitive, they were not specific enough to automatically mandate adjuvant 325 
treatment.  326 
We have demonstrated that adjuvant radiotherapy was associated with a reduced risk of early 327 
recurrence. Nevertheless, limited sample size and inconsistent use of radiotherapy in this cohort 328 
prevents us from making a definitive statement. The role of adjuvant radiotherapy remains to be 329 
determined in prospective studies.  330 
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Overall, the routinely available radiological and histological parameters are insufficient to accurately 331 
predict behaviour and stratify management of patients with this heterogeneous group of tumours. It is 332 
likely that molecular markers, like in other neoplastic diseases, will fill this void and future research 333 
should be focused in this direction. 334 
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Figure 1 519 
Examples of radiological characteristics used in the study. A: peritumoural oedema manifested as T2 520 
hyperintensity immediately surrounding the tumour with mass effect; B: irregular margins with 521 
'mushrooming' and nodules appearing as if detached from main mass of tumour; C: bone involvement 522 
in a parasagittal meningioma; D: sinus involvement manifest with tumour clearly present in the cavity 523 
of the superior sagittal sinus. 524 
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Figure 2 528 
Kaplan-Meier plots demonstrating a significant association between extent of resection; the use of 529 
adjuvant XRT; location (divided into convexity, parafalcine/parasagittal and skull base); peritumoural 530 
oedema and progression free survival for patients with atypical meningiomas. Log rank test for 531 
significance used to determine statistical significance.  532 
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Figure 3 536 
Kaplan-Meier plots demonstrating a significant association between presence of atypia; MI; MIB1 537 
count and progression free survival. MI has been dichotomised to MI ≤ 7/hpf and MI > 7/hpf and 538 
MIB1 has been dichotomised to MIB1 ≤ 15% and MIB1 > 15%. Log rank test for significance used to 539 
determine statistical significance. 540 
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Figure 4 544 
Bar chart demonstrating the difference in clinical outcomes between the 'early progression/recurrence' 545 
groups. All others (top graph); below the same analysis is repeated excluding patient who never had a 546 
recurrence (bottom graph).  Dashed line depicts differences in number of patients with favourable 547 
outcomes defined as mRS 0-1 at last follow-up. mRS - modified Rankin Scale 548 
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Table 1. Baseline characteristics 
 
Factor n= 
n  220 
Female (%)  122 (56%) 
Age, median (IQR)  61 (50-68) 
Recurrence Overall (%) 71 (32%) 
 Recurrence within 1year (%) 18 (8%) 
 Recurrence within 2 years (%) 37 (17%) 
Months to recurrence, 
median (IQR) 
 24 (12-43) 
Location  Convexity (%) 103 (47%) 
 Parafalcine (%) 38 (17%) 
 Skull base (%) 50 (23%) 
 Intraventricular (%) 5 (2%) 
 Sinus involvement (%) 26 (12%) 
STR (%)  62 (28) 
Radiotherapy Adjuvant (%) 57 (26%) 
 For recurrence (%) 34 (16%) 
mRS, median (IQR)  1 (1-3) 
mRS ≤ 1  73% 
mRS ≤ 2  83% 
   
Recurrence within 1 year and within 2 years refers to a recurrence up to and including 12 
months and 24 months post operatively, respectively. IQR - interquartile range; mRS - 
modified Rankin score; STR - subtotal resection 
Table 1
Table 2 Differences in early and any recurrence stratified by location, extent of resection and 
the use of adjuvant radiotherapy.  
 
 n Early recurrence, n (%) Any recurrence, n (%) 
All, GTR 143 17 (12) p=0.005 39 (27) p=0.002 
All, STR 62 20 (32) 31 (50) 
Convexity, GTR 79 5 (6) p=0.001 17 (22) p=0.01 
Convexity, STR 22 7 (32) 11 (50) 
Parafalcine/parasagittal, GTR 18 8 (44) p=0.64 9 (50) p=0.44 
Parafalcine/parasagittal, STR 19 7 (37) 11 (58) 
Skull base, GTR 26 4 (15) p=0.077 9 (35) p=0.14 
Skull base, STR 18 7 (39) 10 (56) 
Sinus involvement, GTR 5 3 (60) p=0.12 4 (80) p=0.27 
Sinus involvement, STR 21 5 (24) 11 (52) 
Adjuvant XRT 57 7 (12) p=0.049 14 (26) p=0.09 
No XRT 140 28 (20) 50 (36) 
Adjuvant XRT, GTR 35 3 (9) p=0.22 9 (26) p=0.61 
Adjuvant XRT, STR 20 4 (20) 5 (25) 
STR - subtotal resection; XRT - adjuvant radiotherapy; any recurrence - defined as recurrence 
within the period of follow-up 
 
Table 2
Table 3 Predictors of recurrence of atypical meningioma - Multivariate regression  
 
  OR 95% CI for OR p 
STR   3.62 1.48-8.88 p=0.005 
Adjuvant XRT  0.38 0.29-0.97 p=0.046 
Location  Convexity 0.85 0.29-2.46 p=0.77 
 Parafalcine 3.81 1.29-11.22 p=0.015 
 Skull base 2.95 0.91-9.62 p=0.07 
Imaging Oedema 4.62 1.19-17.90 p=0.027 
Pathology Atypia 1.14 0.39-3.38 p=0.81 
 MI>7/10 HPF 4.27 1.40-12.19 p=0.007 
CI - confidence interval; HPF - high power field; MI - mitotic index; OR - odds ratio; STR - 
subtotal resection; XRT - radiotherapy 
 
Table 3
Figure 1 Click here to download Figure MRIs.tif 
Figure 2 Click here to download Figure KM _v4_GTR XRT location edema_v2.tif 
Figure 3 Click here to download Figure KM _v4_pathology.tif 
Figure 4 Click here to download Figure mRS by recurrence .tif 
Figure 4 BW Click here to download Figure mRS by recurrence _BW.tif 
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